|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�������� |
|
����� |
| ��������������� | |
|
��Ӣ |
|
�˾� |
| PubMed | |
|
Article by |
|
Article by |
���������²�������о���չ
��Ӣ, �˾�
�ڶ���ҽ��ѧ��������ҽԺƤ���� �Ϻ� 200433
���������ǵڶ����ϳɵķ�����������,���Ķ��俹�����������˽���,��������������������������������������������������������������ıȽϽ��,�Լ��ٴ�Ӧ�ú����������������Эͬ������һ����,Ϊ�ٴ�����������Ƽ���һ���µ���Чҩ�
[2] Sabo JA,Abdel-Rahman SM.Voriconazole:a new triazole antifungal.Ann Pharmacother,2000,34(9):1032-1043.
[3] Hoban DJ,Zhanel GG,Karlowsky JA.In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients.Antimicrob Agents Chemother,1999,43(6):1463-1464.
[4] Vora S,Purimetla N,Brummer E,et al.Activity of voriconazole,a new triazole,combined with neutrophils or monocytes against Candida albicans:effect of granulocyte colony-stimulating factor and granulocytemacrophage colony-stimulating factor.Antimicrob Agents Chemother,1998,42(4):907-910.
[5] Belanger P,Nast CC,Fratti R,et al.Voriconazole(UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible andresistant Candida species.Antimicrob Agents Chemother,1997,41(8):1840-1842.
[6] Fratti RA,Belanger PH,Sanati H,et al.The effect of the new triazole,voriconazole(UK-109,496),on the interactions of Candida albicans and Candida krusei with endothelial cells.J Chemother,1998,10(1):7-16.
[7] Clancy CJ,Nguyen MH.In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species.Eur J Clin Microbiol Infect Dis,1998,17(8):573-575.
[8] Vora S,Chauhan S,Brummer E,et al.Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus:effects of granulocyte colony-stimulating factor and granulocyte-macrophage colonystimulating factor.Antimicrob Agents Chemother,1998,42(9):2299-2303.
[9] Sutton DA,Sanche SE,Revankar SG,et al.In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus,with a head-to-head comparison to voriconazole.J Clin Microbiol,1999,37(7):2343-2345.
[10] Nguyen MH,Yu CY.In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and-resistant Cryptococcus neoformans isolates.Antimicrob Agents Chemother,1998,42(2):471-472.
[11] Radford SA,Johnson EM,Wamock DW.In vitro studies of activity of vodconazole(UK-109,496),a new triazole antifungal agent,against emerging and less-common mold pathogens.Antimicrob Agents Chemother,1997,41(4):841-843.
[12] Arikan S,Lozano-Chiu M,Paetznick V,et al.Microdilution susceptibility testing of amphotericin B,itraconazole,and voriconazole against clinical isolates of Aspergillus and Fusarium species.J Clin Microbiol,1999,37(12):3946-3951.
[13] Fromtling R,CaStaner J.Voriconazole antifungal.Drugs of the future,1996,21:266-271.
[14] Nucci M,Akiti T,Barreiros G,et al.Nosocomial fungemia due to Exophiala jeanselmei var.jeanselmei and a Rhinocladiella species:newly described causes of bloodstream infection.J Clin Microbiol,2001,39(2):514-518.
[15] Espinel-Ingroff A.In vitro fungicidal activities of voriconazole,itraconazole,and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.J Clin Microbiol,2001,39(3):954-958.
[16] Perea S,Fothergill AW,Sutton DA,et al.Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method.J Clin Microbiol,2001,39(1):385-388.
[17] Hughes WT,Bartley DL,Patterson GG,et al.Ketoconazole and candidiasis:a controlled study.J Infect Dis,1983,147(6):1060-1063.
[18] Hegener P,Troke PF,Fatkenheuer G,et al.Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS.AIDS,1998,12(16):2227-2228.
[19] Swift AC,Denning DW.Skull base osteitis following fungal sinusitis.J Laryngol Otol,1998,112(1):92-97.
[20] Weig M,Muller FM.Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.Antimicrob Agents Chemother,2001,45(3):966-968.
[21] Ryder NS,Leitner I.Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species.Med Mycol,2001,39(1):91.